Loqtorzi (toripalimab) is a new investigational medicine for the treatment of advanced nasopharyngeal carcinoma (NPC). Loqtorzi is an anti-PD-1 monoclonal antibody that boosts the body’s immune system response to cancer cells.  Loqtorzi is given as an intravenous infusion.

Is Loqtorzi available yet?

Loqtorzi is not an FDA-approved medicine yet, and will not be available until it has been approved.

A Biologics License Application (BLA) for approval has been made to the FDA for Loqtorzi, and an approval date is expected in the near future. The application for FDA approval was supported by the Phase II clinical study POLARIS-02 and the Phase 3 clinical trial JUPITER-02.

What is Loqtorzi used for?

The Biologics License Application for Loqtorzi is for use in the treatment of:

• advanced recurrent or metastatic nasopharyngeal carcinoma (NPC), when used together with gemcitabine and cisplatin
• or, as a second-line or later treatment for recurrent or metastatic nasopharyngeal carcinoma, after having platinum-containing chemotherapy Loqtorzi can be used as monotherapy.

In the future, Loqtorzi may be used for more cancers. The FDA has also granted Fast Track designation for Loqtorzi to be used for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, mucosal melanoma, nasopharyngeal carcinoma, and small cell lung cancer (SCLC), and soft tissue sarcoma.